Author

James A. Ousey

Observed names: James Ousey, Ousey, James, Ousey, James Anthony

Institution: Arrowhead Pharmaceuticals (United States)

Observed institutions: California Institute of Technology, Pfizer (United States), Arrowhead Pharmaceuticals (United States), Stanford Medicine, Stanford University

ORCID: 0000-0003-4886-0053

Observed ORCID: 0000-0003-4886-0053

OpenAlex ID: A5023594398

Microbiota regulate social behaviour via stress response neurons in the brain

2021 · Wei-Li Wu, Mark D. Adame, et al. · Nature · 357

CRISPR–Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity

2018 · Nicholas J. Kramer, Michael S. Haney, et al. · Nature Genetics · 225

Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens

2018 · Michael S. Haney, Christopher J. Bohlen, et al. · Nature Genetics · 190

Integrated Multi‐Cohort Analysis of the Parkinson's Disease Gut Metagenome

2023 · Joseph C. Boktor, Gil Sharon, et al. · Movement Disorders · 67

Gut microbiota suppress feeding induced by palatable foods

2022 · James Ousey, Joseph C. Boktor, et al. · Current Biology · 63

Endoplasmic reticulum–resident protein 57 (ERp57) oxidatively inactivates human transglutaminase 2

2018 · Michael C. Yi, Arek V. Melkonian, et al. · Journal of Biological Chemistry · 42

Genome-wide synthetic lethal CRISPR screen identifies FIS1 as a genetic interactor of ALS-linked C9ORF72

2019 · Noori Chai, Michael S. Haney, et al. · Brain Research · 23

Population Pharmacokinetic Modeling of Subcutaneous Plozasiran in Healthy Volunteers and Patients with Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia, and Mixed Hyperlipidemia

2025 · James Ousey, Claudia Jomphe, et al. · The Journal of Clinical Pharmacology · 6

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

2026 · James Ousey, Nathalie H Gosselin, et al. · The Journal of Clinical Pharmacology · 2

Meta-analysis of efficacy outcome measures across immune checkpoint inhibitors (ICIs) and targeted therapies (TTs) in melanoma to guide future clinical trial design.

2023 · James Ousey, Sima Ahadieh, et al. · Journal of Clinical Oncology

Works count: 12

Citation count: 975

H-index: 7

I10-index: 7